Ardelyx, Inc. (ARDX) compared with its closest peers (ESPR, ARQT, AVIR, NATR, BBIO). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Esperion Therapeutics, Arcutis Biotherapeutics, Atea Pharmaceuticals, Nature's Sunshine Products, BridgeBio Pharma, Mirum Pharmaceuticals, Ironwood Pharmaceuticals, Rigel Pharmaceuticals, Xeris Biopharma and Catalyst Pharmaceuticals share Ardelyx's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Esperion Therapeutics, Inc. (ESPR) | $821.21M | -33.7 |
| Arcutis Biotherapeutics, Inc. (ARQT) | $3.15B | -223.4 |
| Atea Pharmaceuticals, Inc. (AVIR) | $434.71M | -1.8 |
| Nature's Sunshine Products, Inc. (NATR) | $252.32M | 13.2 |
| BridgeBio Pharma, Inc. (BBIO) | $15.93B | -20.2 |
| Mirum Pharmaceuticals, Inc. (MIRM) | $5.87B | -168.0 |
| Ironwood Pharmaceuticals, Inc. (IRWD) | $708.05M | 4.1 |
| Rigel Pharmaceuticals, Inc. (RIGL) | $857.22M | 13.7 |
| Xeris Biopharma Holdings, Inc. (XERS) | $1.50B | — |
| Catalyst Pharmaceuticals, Inc. (CPRX) | $3.85B | 17.1 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
ARDX overview · ARDX earnings · ARDX financials · ARDX KPIs · ARDX documents · ARDX ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.